FDA Lets MS Drug Tysabri Return

June 5, 2006 -- The FDA is letting the multiple sclerosis (MS)multiple sclerosis (MS) drug Tysabri back on the market under a restricted distribution program.

The FDA first approved Tysabri in November 2004. Tysabri’s maker, Biogen-Idec, took Tysabri off the market in February 2005 after three people out of about 3,000 patients taking Tysabri in clinical trials developed a rare, serious brain infection called progressive multifocal leukoencephalopathy (PML). Two of those patients died.

The FDA is rolling out a risk-minimization plan along with Tysabri's return to the market. The plan is designed to inform patients, doctors, pharmacists, and infusion centers about Tysabri’s risks and to quickly flag PML cases in patients taking Tysabri.

However, FDA officials aren’t ruling out the possibility of more cases of PML in patients taking the drug.

Rare Return to Market

“This is one of the very rare cases in which a drug withdrawn from the market for safety reasons has been returned back to the market after appropriate steps have been taken,” the FDA’s Steven Galson, MD, MPH, told reporters in a conference call.

Galson directs the FDA’s Center for Drug Evaluation and Research. He says the FDA has worked “closely” with Biogen-Idec on the new plan.

In Tysabri’s clinical trials, about one in 1,000 participants developed PML after taking Tysabri for up to two years. It’s not clear if that rate will hold in the general public or for longer use, the FDA’s Russell Katz, MD, told reporters in the teleconference. Katz works in the neurology products division of the FDA’s Center for Drug Evaluation and Research.

PML is still a risk with Tysabri, note both Galson and Katz.

"Without prohibiting use of the drug, you can never be sure that this won’t happen again. But we think that the steps that we’ve taken are prudent to reduce that risk,” Galson says.

More Cases Possible

“There’s much we don’t know about this,” Katz says. “We expect, yes, that there will be other cases and there probably will be additional deaths. This is balanced against the significant benefit that we believe the drug confers,” Katz says.